Therapy for Open-Angle Glaucoma

Marshall, Leisa L.; Hayslett, Renée L; Stevens, Gregg

doi:10.4140/tcp.n.2018.432

Cited by 29 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glaucoma is a neurodegenerative ophthalmologic disease characterized by the progressive degeneration of the retinal ganglion cells and axonal death, resulting in an irreversible blindness ( Marshall et al, 2018 ; Garcia-Medina et al, 2020 ). Glaucoma is commonly related to high intraocular pressure (IOP) with a subsequent injury of the optic nerve, and eventually blindness ( Goel et al, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Glaucoma is one of the most common causes of blindness, thus seriously affecting people’s health and quality of life. The topical medical therapy is as the first line treatment in the management of glaucoma since it is inexpensive, convenient, effective, and safe. This review summarizes and compares extensive clinical trials on the topical medications for the treatment of glaucoma, including topical monotherapy agents, topical fixed-combination agents, topical non-fixed combination agents, and their composition, mechanism of action, efficacy, and adverse effects, which will provide reference for optimal choice of clinical medication. Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma. Meanwhile, we also discuss new trends in the field of new fixed combinations of medications, which may better control IOP and treat glaucoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…First, it is not uncommon for a patient to require more than one class of drugs, and even then, many patients still do not achieve a safe target intraocular pressure (IOP). 7 Second, therapeutic classes have known ocular systemic adverse effects, including beta-adrenergic antagonists with bradycardia, dyspnea, and wheezing, as well as alpha-2 agonists with dry mouth, fatigue, sedation, and dizziness. 8 , 9 Therefore, it is important to develop IOP-lowering therapies for patients with signs of glaucoma progression despite lower IOP with current treatment and also in individuals with normotensive glaucoma (NTG), where patients show progressive structural changes in their optic nerve fibers and/or progressive visual field loss despite IOP in what may be otherwise considered a “normal range.” The Baltimore Eye Survey of 5308 patients found that 78% of eyes with primary open-angle glaucoma had screening IOP of <25 mmHg, indicating the importance of achieving efficacy at these lower IOP levels.…”

Section: Introductionmentioning

confidence: 99%

Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial

Pepose¹,

Hartman²,

DuBiner³

et al. 2021

OPTH

View full text Add to dashboard Cite

“…Control IOP by drugs can appropriately delay the progression of glaucoma. For the target IOP, it should be achieved with the least drugs and side effects (5,6). However, the major problems in treatment are patient compliance and ocular surface toxicity (7).…”

Section: Introductionmentioning

confidence: 99%

XEN gel implant with or without phacoemulsification for glaucoma: a systematic review and meta-analysis

Wang¹,

Leng²,

An³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: XEN gel implant is an alternative method of treating glaucoma by connecting the anterior chamber and the subconjunctival space. The efficacy of the XEN gel implant and whether to combine with phacoemulsification is what most concerned. This review aims to test the efficacy and safety of the XEN gel implant compared with trabeculectomy and to test the efficacy between XEN combined with phacoemulsification and XEN alone.Methods: The PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were searched through July 8, 2020. Studies comparing XEN and trabeculectomy or comparing XEN + phacoemulsification and XEN alone were included. The standard mean differences (SMD) were calculated to analyze the lowered intraocular pressure (IOP) and the number of anti-glaucoma medications. All data were measured from baseline to endpoint. The I2 statistic quantified heterogeneity ranged from 0% to 100%, and a random effects model was used in this meta-analysis. Review Manager 5.3 performed all analyses. The t-test calculated all P values, and P values were regarded as statistically significant at P<0.05. The methodological index for non-randomized studies was used to find and test bias in the literature.Results: Twelve studies with 1,602 eyes were included. Five studies compared the XEN gel implant with trabeculectomy. Eight compared XEN + phacoemulsification with XEN alone. There was no significant correlation between XEN and trabeculectomy groups in lowering IOP (SMD 0.30, 95% CI, 0.00 to 0.60, I²=60%) and reduced the number of IOP lowering drugs (SMD 0.01, 95% CI, -0.16 to 0.17, I²=0%). There was a significant difference between XEN + phacoemulsification and XEN alone in lowering IOP (1,034 eyes, SMD 0.22, 95% CI, 0.05 to 0.40, I²=38%) and reducing the number of medications (729 eyes, SMD 0.20, 95% CI, -0.06 to 0.46, I²=62%).Conclusions: XEN gel implant, although not effective as trabeculectomy, is a safe operation for openangle and some other types of glaucoma. Meanwhile, XEN alone is more effective than XEN combined with phacoemulsification within 1 week after operations. After three months, the two groups are similar in lowering IOP. More extensive, better-designed, strictly blinded, multicenter randomized clinical trials are needed to confirm our findings.

show abstract

Therapy for Open-Angle Glaucoma

Cited by 29 publications

References 0 publications

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial

XEN gel implant with or without phacoemulsification for glaucoma: a systematic review and meta-analysis

Contact Info

Product

Resources

About